Cavet ME, et al. - Researchers explored the efficacy of bepotastine besilate ophthalmic solution (BBOS) 1.5%, a topical antihistamine for the treatment of ocular itching associated with allergic conjunctivitis (AC), in relieving nasal symptoms in an integrated analysis of two Phase III conjunctival allergen challenge (CAC) studies and a Phase IV environmental allergen study. Phase III trials demonstrated BBOS 1.5% -induced reduction in CAC-induced nasal congestion and pruritus at 15 minutes and 8 hours postdosing. Phase IV environmental study revealed BBOS 1.5% reduced sneezing and nasal pruritus over 2 weeks and median number of days to improvement of nasal pruritus and total nasal symptom score. Overall, use of topical ocular BBOS 1.5% for alleviating rhinitis symptoms associated with AC was supported.